Xinguang Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 50.39 million yuan, a decrease of 21.70%

Xinguang Pharma released its 2024 annual report, with operating revenue of 268 million yuan, a year-on-year decrease of 1.01%; net profit attributable to shareholders was 50.39 million yuan, a year-on-year decline of 21.70%; net profit excluding non-recurring gains and losses was 45.394 million yuan, a year-on-year decrease of 24.50%. The basic earnings per share were 0.31 yuan, and it plans to distribute a cash dividend of 3.00 yuan (tax included) for every 10 shares to all shareholders